Loading...
Rising Regulatory Scrutiny And Patent Cliffs Will Curtail Oncology Prospects
AnalystLowTarget's Fair Value
US$250.00
30.9% overvalued intrinsic discount07 Sep
US$327.20
1Y
65.7%7D
-6.8%1Y
65.7%7D
-6.8%You can edit this narrative until Sep 7 10:34 PM. Then, changes will post as Updates.